Patents Examined by James D. Schultz
  • Core/shell structure platform for immunotherapy
    Patent number: 11382964
    Abstract: Disclosed are biocompatible core/shell compositions suitable for the delivery of populations of mRNA molecules to mammalian cells. The disclosed core-shell structured multicomponent compositions are optimized for the delivery of mRNAs encoding one or more cancer- or tumor-specific antigens to a population of antigen presenting cells, including, for example, human dendritic cells, macrophages and B cells. Also disclosed are methods for use of these compositions as therapeutic cancer vaccines.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: July 12, 2022
    Assignee: The Methodist Hospital
    Inventor: Haifa Shen
  • SpyCatcher and SpyTag: universal immune receptors for T cells
    Patent number: 11377481
    Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor that comprises a protein or peptide tag, such as a SpyCatcher or a SpyTag moiety, bound to an extracellular hinge region, a transmembrane domain, and an intracellular domain for T cell activation.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: July 5, 2022
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Daniel Powell, Andrew Tsourkas
  • Measles virus encoding a tumor antigen
    Patent number: 11369669
    Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding at least one of (i) a tumor antigen, (ii) a fragment of a tumor antigen, and (iii) a variant of (i) or (ii). The present invention further relates to a polynucleotide encoding said recombinant virus of the family Paramyxoviridae and to a host cell comprising said recombinant virus of the family Paramyxoviridae and/or said polynucleotide encoding said recombinant virus of the family Paramyxoviridae. Moreover, the present invention relates to a method for activating immune cells with antitumor activity in a sample comprising cancer cells and to further means, methods, and uses related to the present invention.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: June 28, 2022
    Assignee: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
    Inventors: Elena Czink, Christine Engeland, Guy Ungerechts
  • Codon optimized REP1 genes and uses thereof
    Patent number: 11357870
    Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human REP1, vectors, and host cells comprising codon optimized REP1 sequences, and methods of treating retinal disorders such as choroideremia comprising administering to the subject a codon optimized sequence encoding human REP1.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: June 14, 2022
    Assignee: 4D Molecular Therapeutics Inc.
    Inventors: David H. Kirn, Melissa A. Kotterman, Peter Francis
  • BCMA chimeric antigen receptors
    Patent number: 11351236
    Abstract: The invention provides improved compositions for adoptive T cell therapies for B cell related conditions.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: June 7, 2022
    Assignee: 2seventy bio, Inc.
    Inventors: Richard Morgan, Kevin Friedman
  • Method for proliferating neural progenitor cells and composition for treating neurological diseases containing proliferated neural progenitor cells
    Patent number: 11351194
    Abstract: The present invention provides a method for proliferating neural progenitor cells and a composition for treating neurological diseases, the composition including a proliferated neural progenitor cell. When a fetal neural progenitor cell is cultured under a hypoxia condition and/or in a medium containing tocoperol, tocoperol acetate, or a mixture thereof, the improved cell proliferation rates of the fetal neural progenitor cell are confirmed. In addition, considering an effect of the neural progenitor cell on preventing differentiation thereof into neurons at the time of proliferation, the present disclosure may contribute to mass production of neural stem cells, and accordingly, the proliferated neural progenitor cell is expected to be utilized in the treatment of a neurological disease.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: June 7, 2022
    Assignee: CHA BIOTECH CO., LTD.
    Inventors: Jisook Moon, Hyun-Seob Lee, Yeon-Ho Shin
  • Fetal hemoglobin for genetic correction of sickle cell disease
    Patent number: 11345740
    Abstract: Methods and compositions disclosed herein generally relates to methods of determining minimum hematopoietic stem cell (HSC) chimerism and gene dosage for correction of a hematopoietic disease; in particular, in in vivo models. The invention also relates to modified lentiviral expression vectors for increasing a viral titer and various methods for increasing such titers as well as expression vectors capable of enhancing such titers. The invention also relates to CHS4 chromatin insulator-derived functional insulator sequences. The invention also relates to methods for genetic correction of diseases or reducing symptoms thereof, such as sickle cell anemia or ?-thalassemia.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 31, 2022
    Assignee: Children's Hospital Medical Center
    Inventor: Punam Malik
  • Methods and compositions for producing pancreatic beta cells
    Patent number: 11332716
    Abstract: Compositions and methods of producing mammalian cell populations that include a high proportion of pancreatic beta cells are described herein. Such cell populations are useful for treatment of diabetes. Also provided are materials and methods for the direct differentiation of stem cells, such as embryonic stem cells, into functional pancreatic beta cells. The disclosure provides the benefit of direct differentiation, which results in the production of functional pancreatic beta cells efficiently and at low cost.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: May 17, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
    Inventors: Matthias Hebrok, Holger Andreas Russ, Sheng Ding, Saiyong Zhu
  • Methods and compositions for targeted genetic modification through single-step multiple targeting
    Patent number: 11326184
    Abstract: Methods and compositions are provided for making one or more targeted genetic modifications at a target genomic locus within a cell and for producing non-human animals comprising the modified genomic locus. The methods employ two or more large targeting vectors which are capable of recombining with each other and with the target genomic locus in a single genomic targeting step. The methods may also be employed in combination with a nuclease agent. Methods and compositions are also provided for enhancing homologous recombination at a target genomic locus in a cell. The methods employ two or more nucleic acids comprising one or more overlapping sequences. The methods may be employed in combination with a nuclease agent or without a nuclease agent.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: May 10, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Vera Voronina, Lynn Macdonald, Brian Zambrowicz, Andrew J. Murphy
  • Method for non surgical repair of vertebral compression fractures
    Patent number: 11318166
    Abstract: Described herein are methods and compositions using PTH and mesenchymal stem cells (MSCs) for treatment of osteoporosis, bone fractures, and related conditions. Administration of both PTH and MSCs leads to increased homing of MSCs to sites of vertebral bone and rib fracture. The described methods and compositions provide therapeutic approaches that rely, in-part, on stem cell capacity for regeneration and repair. The potential for enhanced bone formation and fracture repair may allow for both preventative and palliative treatments in osteoporotic patients, with combined PTH+MSC therapy producing bone regeneration capacity that is significantly superior to either treatment alone.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: May 3, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dan Gazit, Edward M. Schwarz, Hyun Bae, Gadi Pelled, Zulma Gazit, Dmitriy Sheyn, Wafa Tawackoli
  • Isolation of fusion-competent myoblasts and therapeutic applications thereof related to muscular dystrophy
    Patent number: 11318167
    Abstract: Described are methods of isolating high purity myoblasts that are used to create novel DMD model systems and methods using human induced pluripotent stem cells (hiPSCs). Also described are therapeutic methods based on the use of these myoblasts.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 3, 2022
    Assignee: The Johns Hopkins University
    Inventors: Gabsang Lee, InYoung Choi, HoTae Lim, Kathryn R. Wagner
  • Taurine supplemented cell culture medium and methods of use
    Patent number: 11312936
    Abstract: The specification describes a composition comprising an improved eukaryotic cell culture medium, which can be used for the production of a protein of interest. Taurine can be added to serum-free media or chemically-defined media to increase the production of a protein of interest. Methods for recombinantly expressing high levels of protein using the media compositions are included.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: April 26, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Amy S. Johnson, Meghan E. Casey, Shadia Oshodi, Shawn Lawrence
  • AAV vectors produced by insect cells comprising REP52 and REP78 coding sequences with differential codon biases
    Patent number: 11306291
    Abstract: The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: April 19, 2022
    Assignee: UNIQURE IP B.V.
    Inventors: Andrew Christian Bakker, Wilhelmus Theodorus Johannes Maria Christiaan Hermens
  • Expression process
    Patent number: 11306323
    Abstract: A process for the production of a target polypeptide is provided. The process comprises expression of an expression vector for expressing a target polypeptide in a host cell, preferably a mammalian cell, the expression vector comprising an expression cassette comprising a polynucleotide encoding a recombinant polypeptide operably linked to a fibronectin secretion leader sequence; and recovering the target polypeptide.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: April 19, 2022
    Assignee: Fujifilm Diosynth Biotechnologies UK Limited
    Inventors: Fay Louise Saunders, Anna Louise Dodds, Adeline Marie Geraldine Bayard, Bhupendra Vallabh Kara
  • Cryopreservation of viable human skin substitutes
    Patent number: 11297829
    Abstract: The present invention relates generally to systems and methods for preparing, storing, shipping and using skin equivalents made by organotypic culture. In particular, the present invention relates to systems and methods for cryopreserving viable skin substitutes.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: April 12, 2022
    Assignee: Stratatech Corporation
    Inventors: B. Lynn Allen-Hoffmann, John C. Pirnstill, Kenneth R. Gratz, Allen R. Comer
  • Genetic modification of pigs for xenotransplantation
    Patent number: 11284607
    Abstract: The invention provides for transgenic donor animals (e.g., pigs) whose cells, tissues and organs have a better long-term survival when transplanted into a human patient. The transgenic donor animal carries one or more human transgenes which is expressed only when the endogenous gene of the donor animal is knocked out shortly before a graft is harvested for transplantation. This “genetic switch” allows the donor animal to remain healthy during the majority of its lifetime, while still allowing expression of the human transgene for optimal transplant tolerance in a human recipient. The transgene may encode a cytokine receptor, an adhesion molecule, or a complement regulatory protein.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: March 29, 2022
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventor: Megan Sykes
  • Method for suppressing tumors by miR-200 family inhibition
    Patent number: 11285168
    Abstract: Tumor growth was found to be significantly suppressed in vivo by inhibiting both miRNA containing 5?-AACACUG-3? as a seed sequence and miRNA containing 5?-AAUACUG-3? as a seed sequence. The inhibition significantly altered the proportion of subpopulations of tumor cells and reduced the tumorigenicity in all subpopulations. The inhibition also exerted a remarkable tumor-shrinking effect on already-formed tumors. The present invention provides novel therapeutic potential against tumor.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: March 29, 2022
    Assignee: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Hideo Iba, Takeshi Haraguchi
  • Cell culturing method using nucleic acid-containing medium
    Patent number: 11286459
    Abstract: An object of the present invention is to provide an animal cell culture method which is high in protein productivity. Provided is a method for culturing animal cells in a culture medium, wherein the culture medium comprises a nucleic acid component(s) (deoxyuridine, thymidine, and/or deoxycytidine, or a salt(s) thereof). Also provided is a method for producing a protein, the method comprising the step of culturing animal cells expressing the protein in a culture medium, wherein the culture medium comprises a nucleic acid component(s).
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: March 29, 2022
    Assignee: Astellas Pharma Inc.
    Inventors: Yasuhiro Takagi, Takuya Kikuchi
  • Tolerogenic DNA vaccine
    Patent number: 11279745
    Abstract: The present invention relates to plasmids useful for prevention and/or delay of e.g. type 1 diabetes.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: March 22, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Jay Chaplin, Michael Wijaranakula
  • Tumor infiltrating cells engineered to express a pro-inflammatory polypeptide
    Patent number: 11273177
    Abstract: The present disclosure provides methods of preparing tumor infiltrating cells engineered to express a pro-inflammatory polypeptide. The pro-inflammatory polypeptide is expressed from the tumor infiltrating cell to counter a generally immunosuppressive state in and around tumors resulting from an imbalance between the number and activation state of immune effector cells versus those of suppressor cells. Delivering the proinflammatory polypeptide via expression from the TICs, as distinct from systemic administration, reduces side effects from increased inflammation at sides remote from a tumor to be treated.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: March 15, 2022
    Assignee: Berkeley Lights, Inc.
    Inventors: Kevin T Chapman, Xiaohua Wang, Xiao Guan Radstrom, Yelena Bronevetsky, Guido K Stadler, Gregory G Lavieu, Annamaria Mocciaro